Related Experiment Video
Updated: Jul 3, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency
Li-Qiang Zhao1, Su Han, Hao-Ming Tian
1Department of Endocrinology, West China Hospital of Sichuan University, Chengdu 610000, China.
Background:
11beta-hydroxylase deficiency is one of the main causes of congenital adrenal hyperplasia (CAH). It is caused by the mutation of the CYP11B1 gene that encodes the enzyme. Researches have shown that mutations of the CYP11B1 gene would result in activity decrease or inactivation of the enzyme in classical 11beta-hydroxylase deficiency.
Data Sources:
Articles on CAH and CYP11B1 gene mutation were retrieved from PubMed and MEDLINE published after 1991.
Results:
The prevalence, pathophysiology, and molecular-genetic mechanisms were summarized.
Conclusions:
The disease is caused by genetic mutations of CYP11B1, and types of the mutations are varied. In classical 11beta-hydroxylase deficiency, genetic mutations of CYP11B1 lead to activity decrease or loss; mutations in unclassical 11beta-hydroxylase deficiency are not definite. And the relationship between genotype and phenotype is not established.
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Pharmacogenomics: Identification of New Drug Targets
Smooth Endoplasmic Reticulum
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pedigree Analysis
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

